Sofinnova Partners Launches Three New Biotechs with €165M Acceleration Fund
Sofinnova Partners closed its Biovelocita II fund, raising €165 million ($180 million), exceeding its target15.
The fund received substantial backing from major pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures15.
Biovelocita II is now the largest Pan-European biotech accelerator, expanding beyond Italy to include France, the UK, and Denmark17.
Three new biotech companies have been launched with support from the fund10:
BioClec:
Focused on breakthrough therapies for Alzheimer's disease17.
Forth Therapeutics:
A University of Edinburgh spin-out developing next-generation precision therapeutics for fibrosis17.
Signadori Bio:
A novel cell therapy platform developed from research at the Gustave Roussy Institute178.
The fund has screened over 300 projects since its launch and plans to continue investing in innovative startups across Europe17.
Sofinnova Partners, founded in 1972, is a leading European life sciences venture capital firm managing over €4 billion in assets17.
The Biovelocita strategy offers scientific founders a comprehensive framework, combining direct management, financial support, and access to Sofinnova's extensive network17.
Sources:
1. https://www.businesswire.com/news/home/20250318305639/en/Sofinnova-Partners-Exceeds-Target-With-%E2%82%AC165M-Biotech-Acceleration-Fund-Europes-Largest-With-Strong-Pharma-Support
5. https://www.fiercebiotech.com/biotech/european-vc-firm-sofinnova-brings-home-eu165m-biotech-acceleration-fund-support-amgen-bms
7. https://sofinnovapartners.com/news/Sofinnova%20Partners%20exceeds%20target%20with%20%E2%82%AC165M%20biotech%20acceleration%20fund,%20Europe%E2%80%99s%20largest,%20with%20strong%20Pharma%20support
8. https://sofinnovapartners.com/news/sofinnova-partners-and-gustave-roussy-launch-first-biotech-company-through-strategic-partnership